Given the role Tregs play in inhibiting effector T cells and suppressing anti-tumor immunity, multiple agents with anti-Treg activity have been evaluated across different tumor types, including cytotoxic agents like cyclophosphamide [29] and immune interventions such as anti-CTLA-4 antibodies [30]. This evidence concerns the gene CTLA4 and neoplasm.